{"id":2870,"date":"2026-08-31T11:00:00","date_gmt":"2026-08-31T15:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2870"},"modified":"2026-09-04T16:45:35","modified_gmt":"2026-09-04T20:45:35","slug":"fda-expands-besremi-to-adults-with-essential-thrombocythemia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2870","title":{"rendered":"FDA Expands Besremi to Adults With Essential Thrombocythemia"},"content":{"rendered":"

Company:<\/strong> PharmaEssentia · Drug:<\/strong> Besremi (Ropeginterferon Alfa-2b-njft) · Indication:<\/strong> Essential Thrombocythemia · Trial:<\/strong> SURPASS-ET (Phase III) · Date:<\/strong> August 31, 2026<\/p>\n

\"FDA<\/p>\n

Summary<\/h4>\n

FDA approved ropeginterferon alfa-2b-njft, marketed as Besremi, for adults with essential thrombocythemia regardless of genotype or disease status. The decision creates a long-acting interferon option across the labeled adult population and represents the first new U.S. therapy for ET in nearly three decades. The pivotal evidence, however, came from patients with inadequate response or intolerance to hydroxyurea, making extrapolation to treatment-naive or otherwise stable patients an important evidence boundary.<\/p>\n

What Happened<\/h4>\n

Approval was supported by SURPASS-ET, an open-label randomized study of 174 adults with high-risk ET who were resistant or intolerant to hydroxyurea. Participants received Besremi or anagrelide, with low-dose aspirin unless contraindicated. Durable modified European LeukemiaNet response at months 9 and 12 occurred in 37.4% of 91 Besremi-treated patients and 3.6% of 83 anagrelide-treated patients. The labeled regimen begins at 250 micrograms subcutaneously, increases to 350 micrograms at week two and 500 micrograms at week four, then continues at 500 micrograms every two weeks unless modified. Common adverse reactions included transaminase elevations, anemia, fever, bacterial infection, pruritus and weight loss. The interferon-class boxed warning covers serious neuropsychiatric, autoimmune, ischemic and infectious disorders.<\/p>\n

Deep Analysis<\/h4>\n

Besremi provides sustained type I interferon signaling intended to suppress the malignant myeloproliferative clone while controlling platelet counts and disease features. Unlike purely cytoreductive approaches, interferon can reduce mutant-allele burden in some myeloproliferative neoplasms, but molecular response is not established as a surrogate for fewer thromboses, progression to myelofibrosis or transformation to acute leukemia. A large durable-response difference against an active comparator, infrequent dosing and a genotype-agnostic label support a clinically useful option for hydroxyurea-intolerant or resistant patients, and longer follow-up showing fewer vascular events, durable hematologic control and manageable discontinuation would strengthen this interpretation. The broad label may exceed the randomized evidence base, however, because SURPASS-ET enrolled hydroxyurea-inadequate or intolerant patients; open-label assessment, interferon tolerability and lack of mature thrombosis or disease-progression outcomes could limit uptake outside that group, and higher discontinuation, toxicity-driven dose reduction or weak real-world persistence would support this narrower view.<\/p>\n

Company and Product Background<\/h4>\n

PharmaEssentia develops long-acting biologics for myeloproliferative neoplasms. Besremi is a mono-pegylated interferon alfa-2b with extended exposure that activates interferon receptors and downstream JAK-STAT signaling. It was previously approved in the United States for polycythemia vera. Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by clonal megakaryocyte proliferation and elevated platelet counts, often driven by JAK2, CALR or MPL mutations. Treatment aims to reduce thrombosis and bleeding while controlling symptoms and limiting disease progression.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Status<\/td>\nFDA approval, all adults with ET regardless of genotype\/disease status<\/td>\n<\/tr>\n
Pivotal Trial<\/td>\nSURPASS-ET, 174 patients, hydroxyurea-resistant\/intolerant high-risk ET<\/td>\n<\/tr>\n
Efficacy<\/td>\nDurable mELN response 37.4% (Besremi) vs. 3.6% (anagrelide)<\/td>\n<\/tr>\n
Safety<\/td>\nBoxed warning: neuropsychiatric, autoimmune, ischemic, infectious disorders<\/td>\n<\/tr>\n
Context<\/td>\nFirst new U.S. ET therapy in nearly three decades<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A large durable-response difference against an active comparator (37.4% vs. 3.6%), infrequent every-two-week dosing and a genotype-agnostic label support a clinically meaningful new option for hydroxyurea-intolerant or resistant high-risk ET patients after nearly three decades without a new therapy.<\/p>\n

Bear case:<\/strong> The broad adult label may exceed the randomized evidence base, since SURPASS-ET enrolled only hydroxyurea-inadequate or intolerant patients in an open-label design, and mature thrombosis, progression and overall-survival outcomes needed to confirm disease-modifying benefit remain unreported.<\/p>\n

InSilens Take<\/h4>\n

The approval is a material hematology signal because it adds a disease-modifying therapeutic concept to an old treatment landscape and carries a broad adult label. Direction is positive, but the strongest evidence applies to hydroxyurea-resistant or intolerant high-risk disease. Uptake and long-term value will depend on tolerability, persistence and whether hematologic or molecular control translates into fewer clinical events.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate-high on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA approved ropeginterferon alfa-2b-njft, marketed as Besremi, for adults with essential thrombocythemia regardless of genotype or disease status. The decision creates a long-acting interferon option across the labeled adult population and represents the first…<\/p>\n","protected":false},"author":1,"featured_media":2878,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[541,543,540,542],"class_list":["post-2870","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-besremi","tag-essential-thrombocythemia","tag-pharmaessentia","tag-ropeginterferon"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2870"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2870\/revisions"}],"predecessor-version":[{"id":2895,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2870\/revisions\/2895"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2878"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}